Patents Examined by Cecilia M. Jaisle
  • Patent number: 8507410
    Abstract: A pyridazinone compound represented by formula (I) wherein R1 represents a C1-6 alkyl group or a (C1-6 alkyloxy) C1-6 alkyl group, R2 and R3 represent hydrogen or a C1-6 alkyl group, W represents halogen, etc., Z1 represents a C1-6 alkyl group, Z2 represents a C1-6 alkyl group, a C3-8 cycloalkyl group, etc., and n represents 0, 1, 2, 3 or 4, has a weed-controlling effect and an arthropod-controlling effect.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: August 13, 2013
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Takafumi Fusaka
  • Patent number: 8501731
    Abstract: The present invention relates to a class of pyridazinones of formula I, which comprises 6-[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one as a mother nucleus, the preparation method thereof and the use thereof in manufacturing medicaments against tumors, especially liver cancer.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 6, 2013
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Youhong Hu, Liguang Lou, Shijun Lin, Hongbing Zhao, Zhende Liu, Yongping Xu, Bo Chao
  • Patent number: 8497265
    Abstract: Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: July 30, 2013
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Holger Monenschein, Thomas T. Nguyen, Andreas Reichelt, Robert M. Rzasa
  • Patent number: 8497278
    Abstract: Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed. Many of the compounds disclosed herein may be represented by the following generic formula: in which Y is a direct bond or heteroatom and A3 is usually a nitrogenous heterocycle.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: July 30, 2013
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Qun Kevin Fang, Frank Xinhe Wu, Paul T. Grover, Seth C. Hopkins, Una Campbell, Milan Chytil, Kerry L. Spear
  • Patent number: 8481542
    Abstract: The present invention relates to compounds of formula I: in which R11 and R12 are defined in the Summary of the Invention; capable of inhibiting the Hedgehog and Smo signaling pathway. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the diagnosis and treatment of pathologies relating to the Hedgehog and Smo signaling pathway, for example, tumor formation, cancer, neoplasia and non-malignant hyperproliferative disorders.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 9, 2013
    Assignee: Novartis AG
    Inventors: Feng He, Stefan Peukert, Karen Miller-Moslin, Naeem Yusuff, Zhuoliang Chen, Bharat Lagu
  • Patent number: 8481727
    Abstract: Provided are novel crystals of 4-bromo-6-(3-(4-chloro-phenyl)propoxy)-5-(pyridin-3-ylmethylamino)pyridazin-3(2H)-one monohydrochloride, and a process for production of same. A-form crystals of 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(pyridin-3-ylmethylamino)pyridazin-3(2H)-one monohydro-chloride represented by formula (1), which exhibit a powder X-ray diffraction pattern with characteristic peaks at diffraction angles (2?) of 8.24, 11.24, 11.76, 16.48, 17.16, 17.80, 18.24, 19.80, 21.64, 22.56, 22.96, 23.68, 24.52, 25.92, 26.32, 27.12, 27.40, 28.00, 28.64, 29.28, 31.84 and 34.80°.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 9, 2013
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Shiro Kawahara, Junichi Nishitani
  • Patent number: 8481538
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: July 9, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Aronov, Jon Come, John Court, David Deininger, David Lauffer, Pan Li, Kira McGinty, Suganthini Nanthakumar, Dean Stamos, Kirk Tanner
  • Patent number: 8481537
    Abstract: The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: July 9, 2013
    Assignee: LG Life Sciences Ltd.
    Inventors: Hye Kyung Chang, Yeong Soo Oh, Yong Jin Jang
  • Patent number: 8470837
    Abstract: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the presently described compounds.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: June 25, 2013
    Assignee: Takeda Pharmaceutical Company Limted
    Inventors: Qing Dong, Stephen W. Kaldor
  • Patent number: 8470738
    Abstract: There is provided a compound represented by the formula (I): wherein R1 is a C1-6 alkyl group or a (C1-6 alkyloxy)C1-6 alkyl group; R2 is a hydrogen atom or a C1-6 alkyl group; G is a hydrogen atom etc.; Z1 is a C1-6 alkyl group or a C1-6 alkyloxy group; Z2 is a C3-8 cycloalkyl group, etc.; Z3 is a C1-6 alkyl group, etc.; n is 0, 1, 2 or 3, which has an excellent weed controlling effect.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: June 25, 2013
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Takafumi Fusaka
  • Patent number: 8455489
    Abstract: Novel compositions and methods of using substituted pyrimidines which have the general formula: (I).
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: June 4, 2013
    Assignee: Exelixis, Inc.
    Inventors: Richard Martin, Raju Mohan, Peter Ordentlich
  • Patent number: 8455491
    Abstract: The invention relates to the 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to general formula (I): Wherein R2, R7, R8, A, L and B are as defined herein. Also disclosed are the preparative methods and therapeutic use thereof.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 4, 2013
    Assignee: Sanofi
    Inventors: Frederic Puech, Yulin Chiang, Sylvain Cote Des Combes, Adrien Tak Li, Philippe Burnier
  • Patent number: 8450319
    Abstract: The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): useful, for example, as an anti-inflammatory agent or an inhibitor of respiratory tract contraction.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: May 28, 2013
    Assignee: Ube Industries, Ltd.
    Inventors: Masahiko Hagihara, Masayuki Tanaka, Tetsushi Katsube, Makoto Okudo, Noriaki Iwase, Manabu Shigetomi, Tomoko Kanda, Takayuki Nakanishi
  • Patent number: 8445494
    Abstract: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: May 21, 2013
    Assignees: Bristol-Myers Squibb Company, Albany Molecular Research, Inc.
    Inventors: Jun Qiu, Qi Gao, Shuang Liu, Matthew Isherwood
  • Patent number: 8445493
    Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: May 21, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
  • Patent number: 8440666
    Abstract: Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: May 14, 2013
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Yukihiro Shigeta, Yutaka Hirokawa, Hiroshi Nagai, Kei Nagae, Tsuneo Watanabe, Megumi Io, Yusuke Shintani, Junji Kamon, Masato Horikawa, Kazuya Takeuchi
  • Patent number: 8435981
    Abstract: Compounds of the formula (I) in which R1, R2, R3, R4 and R5 have the meanings indicated in claim 1 are inhibitors of tyrosine kinases, in particular of met kinase and can be employed inter alia for the treatment of tumors.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: May 7, 2013
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Dieter Dorsch, Oliver Schadt, Andree Blaukat, Frank Stieber
  • Patent number: 8426412
    Abstract: This invention relates to certain novel 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones such as those illustrated in Formula I and to the use of these compounds for control of fungal pathogens of plants and mammals.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: April 23, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: Martha Kelly, Ronald Ross, Jr., David H. Young
  • Patent number: 8426441
    Abstract: This application discloses novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives according to Formulae I-VI: wherein R, R?, R?, Q, X, and Y are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-VI and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: April 23, 2013
    Assignee: Roche Palo Alto LLC
    Inventors: Nolan James Dewdney, Yan Lou, Michael Soth
  • Patent number: 8420811
    Abstract: Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. Also disclosed are pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression and other conditions and methods for obtaining the crystalline form.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: April 16, 2013
    Assignees: Bristol-Myers Squibb Company, Albany Molecular Research, Inc.
    Inventors: Paul Lobben, Rulin Zhao, Bei Wang, Bang-Chi Chen, Shuang Liu, Min Hu, Yuh-Lin Allen Yang, Matthew Isherwood, Rasidul Amin, Wenge Cui